Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.45 |
| ▸ | BMPR1A | P36894 | 3/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661549 | 1.00 | KMT2A (0.53) | KMT2AGAAMEN1MAPTBMPR1B | |
| SCHEMBL5506594 | 0.93 | MEN1 (0.51) | KMT2AGAAMEN1MAPTBMPR1B | |
| SCHEMBL8127050 | 0.87 | SIRT2 (0.49) | KMT2AGAAMEN1MAPTCASP6 | |
| SCHEMBL5108618 | 0.86 | GAA (0.49) | KMT2AGAAMEN1MAPTCASP6 | |
| SCHEMBL5115938 | 0.85 | GAA (0.48) | KMT2AGAAMEN1MAPTCASP6 | |
| SCHEMBL2061340 | 0.85 | CASP6 (0.52) | KMT2AGAAMEN1MAPTCASP6 | |
| SCHEMBL23055602 | 0.83 | MEN1 (0.46) | KMT2AGAAMEN1MAPTCASP6 | |
| SCHEMBL5503760 | 0.80 | KMT2A (0.46) | KMT2AGAAMEN1MAPTCASP6 | |
| SCHEMBL1231915 | 0.80 | GAA (0.57) | KMT2AGAAMEN1CASP6POLB | |
| SCHEMBL30663251 | 0.80 | GAA (0.57) | KMT2AGAAMEN1CASP6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736854-A2 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4514473-B1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-10-16 | — | — | US | disclosed |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | CELGENE CORPORATION (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2025059429-A1 | MODULATORS OF BCL6 FOR USE IN A METHOD OF TREATING A CANCER OR AN AUTOIMMUNE DISEASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-03-20 | — | — | WO | disclosed |
| CN-119604493-A | Heterocyclic compounds as BCL6 modulators useful as ligand-directed degradants | 细胞基因公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4514473-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2023212147-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| CN-101155806-A | Oxindole * oxazolidinones as antibacterial agents | PHARMACIA & UPJOHN CO LTD (US) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869029-A1 | AN OXINDOLE OXAZOLIDINONE AS ANTIBACTERIAL AGENT | Pharmacia & Upjohn Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2007091147-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1781642-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781643-A1 | OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006106426-A1 | AN OXINDOLE OXAZOLIDINONE AS ANTIBACTERIAL AGENT | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | JOSYULA VARA PRASAD V N | 2006-10-12 | — | — | US | disclosed |
| WO-2006016221-A1 | OXAZOLIDINONES CONTAINING OXINDOLES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006016220-A1 | OXINDOLE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | LUEHR GARY W | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229348-A1 | Oxindole oxazolidinone as antibacterial agent | OXA1L, MRPL21, RPS27L | KMT2A 2830/4885GAA 4493/4885MEN1 2136/4885 |
| US-12404239-B2 | Modulators of BCL6 as ligand directed degraders | BCL6, BCL6B, BCL3 | KMT2A 365/4885GAA 3440/4885MEN1 1223/4885 |
| US-20250320183-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | KMT2A 365/4885GAA 3440/4885MEN1 1223/4885 |
| US-20240025851-A1 | Modulators of BCL6 as Ligand Directed Degraders | BCL6, BCL6B, BCL3 | KMT2A 365/4885GAA 3440/4885MEN1 1223/4885 |
| US-20060030609-A1 | Oxazolidinones containing oxindoles as antibacterial agents | OXA1L, OXSR1, OXER1 | KMT2A 3894/4885GAA 4408/4885MEN1 1292/4885 |
| US-11795147-B2 | Modulators of complex I | NDUFAB1, NDUFV1, NDUFB7 | KMT2A 3543/4885GAA 1788/4885MEN1 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.